John Green
Director of Finance/CFO bij COGENT BIOSCIENCES, INC.
Vermogen: 25 812 $ op 31-03-2024
Profiel
John L.
Green is currently the Chief Financial Officer at Cogent Biosciences, Inc. He previously held positions as the Chief Financial Officer & Accounting Director at Dicerna Pharmaceuticals, Inc. from 2014 to 2020, Assurance Manager at PricewaterhouseCoopers LLP from 2008 to 2013, Vice President & Assistant Treasurer at TSI Corp from 1989 to 1994, Chief Accounting Officer at Merrimack Pharmaceuticals, Inc. from 2017 to 2018, Vice President-Finance at On-Q-ity, Inc. in 2011 to 2012, Senior Manager at Corporate Finance Group, Inc. in 2013 to 2014, Chief Financial Officer at Verastem, Inc. from 2013 to 2016, Controller at Fractyl Health, Inc. from 2015 to 2017, and Chief Financial Officer & Senior Vice President at rEVO Biologics, Inc. from 2002 to 2010.
He obtained his undergraduate degree from College of the Holy Cross (Massachusetts), another undergraduate degree from Acadia University, and an MBA from Questrom School of Business.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
COGENT BIOSCIENCES, INC.
0.00% | 23-01-2024 | 3 841 ( 0.00% ) | 25 812 $ | 31-03-2024 |
Actieve functies van John Green
| Bedrijven | Functie | Begin |
|---|---|---|
| COGENT BIOSCIENCES, INC. | Director of Finance/CFO | 01-06-2018 |
Eerdere bekende functies van John Green
| Bedrijven | Functie | Einde |
|---|---|---|
| DICERNA PHARMACEUTICALS, INC. | Director of Finance/CFO | 26-05-2020 |
| MERRIMACK PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 01-06-2018 |
| FRACTYL HEALTH, INC. | Comptroller/Controller/Auditor | 01-03-2017 |
| VERASTEM, INC. | Director of Finance/CFO | 15-04-2016 |
Opleiding van John Green
| College of the Holy Cross (Massachusetts) | Undergraduate Degree |
| Questrom School of Business | Masters Business Admin |
| Acadia University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| VERASTEM, INC. | Health Technology |
| COGENT BIOSCIENCES, INC. | Health Technology |
| MERRIMACK PHARMACEUTICALS, INC. | Health Technology |
| FRACTYL HEALTH, INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
PricewaterhouseCoopers LLP
 PricewaterhouseCoopers LLP Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers LLC provides assurance, tax and advisory services. Its services include audit and assurance, consulting, deals, human resources, legal, tax, and family business. The firm also offers accountability, risk management, structuring, mergers and acquisitions, and performance and process improvement. The company was founded in 1998 and is headquartered in Buffalo, NY. | Commercial Services |
Dicerna Pharmaceuticals, Inc.
 Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. | Health Technology |
On-Q-ity, Inc.
 On-Q-ity, Inc. Medical/Nursing ServicesHealth Services On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships. | Health Services |
rEVO Biologics, Inc.
 rEVO Biologics, Inc. BiotechnologyHealth Technology rEVO Biologics, Inc. engages in the development and commercialization of specialty therapeutics to address unmet medical needs in patients with rare, life-threatening conditions. Its products include ATryn, which prevents blood clots during and after surgery and childbirth for patients with hereditary antithrombin deficiency. The company was founded in February 1993 and is headquartered in Framingham, MA. | Health Technology |
